Merck KGaA Draws A Line Under “Old” R&D, Now Seeks More Deals
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s Merck KGaA has streamlined its R&D pipeline, concentrating on immuno-oncology, early-stage compounds and collaborative efforts with partners, and discontinuing expensive late-stage products that were going nowhere.
You may also be interested in...
Pfizer Seizes Long-Term Immuno-Oncology Opportunity With Merck Deal
Pfizer partnered with Germany’s Merck KGAA to develop and commercialize an anti-PD-L1 checkpoint inhibitor in clinical development, paying $850 million upfront to catch up to the competition.
Merck Serono/Dr. Reddy's Biosimilars Deal Includes Co-Commercialization In U.S.
In most of the world, Germany's Merck Serono will have exclusive rights and India’s Dr. Reddy's will receive royalties on the oncology biosimilars which will be developed as part of the collaboration; but in the U.S. and select emerging markets, the Indian company retains co-commercialization rights.
Merck KGAA Begins Transformation Effort By Closing Geneva Site
The efficiency program outlined by the German pharma in February will mean elimination of 500 Merck Serono staff in Switzerland, with another 750 employees being redeployed to Germany, China or the U.S.